Medical Condition News

RSS

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.

15 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

Working memory maintenance linked with synchronisation of neurons

A research project of the Neuroscience Center of the University of Helsinki sheds light on the neuronal mechanisms sustaining memory traces of visual stimuli in the human brain. The results show that the maintenance of working memory is associated with synchronisation of neurons, which facilitates communication between different parts of the brain. On the basis of interaction between the brain areas, it was even possible to predict the subject's individual working memory capacity.

15 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

GE and U.S. Army to evaluate deployed soldiers for TBI and PTSD symptoms

As part of GE's continuing efforts to support U.S. troops, GE Global Research, the technology development arm of the General Electric Company, is engaged in a two-year research study with the U.S. Army to evaluate soldiers returning from Iraq and Afghanistan for traumatic brain injuries (TBI) and post-traumatic stress disorders (PTSD).

15 Apr 2010

Gene causing progressive form of hair loss identified

A team of investigators from Columbia, Rockefeller and Stanford Universities has identified a new gene involved in hair growth, as reported in a paper in the April 15 issue of Nature. This discovery may affect future research and treatments for male pattern baldness and other forms of hair loss.

15 Apr 2010

MDA awards over $21M in grants for advancing critical neuromuscular research

Forty-two medical researchers and their labs have been awarded more than $21 million in grants by the Muscular Dystrophy Association to advance critical neuromuscular research in 2010. Many of the grants are multi-year awards to be dispersed over the next three years.

15 Apr 2010

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

Medication and behavioural interventions help children with Attention Deficit Hyperactivity Disorder (ADHD) better maintain attention and self control by normalising activity in the same brain systems, according to researchers at The University of Nottingham.

15 Apr 2010

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

Tobacco policies reduce exposure to secondhand smoke: The Cochrane Library

In countries and states that have introduced policies that restrict smoking in public, people have less exposure to secondhand smoke. There is also a reduction in the number of people who have heart attacks, as well as an improvement in other indicators of health. These findings are reported in a new review published in the April issue of The Cochrane Library.

15 Apr 2010

Gene defect promotes aggressive forms of ovarian cancer

CANCER RESEARCH UK scientists have discovered how mistakes in a key gene drive the early stages of aggressive ovarian cancers. This could improve diagnosis of aggressive forms of the disease and lead to new treatments, according to a study published in the Journal of Pathology this month.

15 Apr 2010

Scientists uncover new genes responsible for cancer, deafness

From deep within the genomes of organisms as diverse as plants, worms and yeast, scientists have uncovered new genes responsible for causing human diseases such as cancer and deafness.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Medical Condition News

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Early, accurate detection of superficial bladder cancer with Olympus PDD

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

Decoding genomes from 25,000 cancer samples

EU Joint Programming initiative to tackle neurodegenerative diseases

Working memory maintenance linked with synchronisation of neurons

Study: Atorvastatin may slow down MS progression

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

GE and U.S. Army to evaluate deployed soldiers for TBI and PTSD symptoms

Gene causing progressive form of hair loss identified

MDA awards over $21M in grants for advancing critical neuromuscular research

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Tobacco policies reduce exposure to secondhand smoke: The Cochrane Library

Gene defect promotes aggressive forms of ovarian cancer

Scientists uncover new genes responsible for cancer, deafness

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News